SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Files An 8-K Submission of Matters to a Vote of Security Holders

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Files An 8-K Submission of Matters to a Vote of Security Holders

Story continues below

Item5.07

Submission of matters to a vote of Security
Holders.

At the 2017 Annual Meeting of Stockholders of the Company held on
June8, 2017 (the Annual Meeting), the matters on which the
stockholders voted, in person or by proxy were:

(i) To elect six nominees as directors to serve until the next
Annual Meeting and until their successors have been elected
and qualified;
(ii) To approve, on an advisory basis, the compensation of the
Companys named executive officers as disclosed in the
Companys Proxy Statement;
(iii) To approve, on an advisory basis, the frequency of future
advisory votes on Companys named executive officer
compensation;
(iv) To ratify the selection of PricewaterhouseCoopers Zhong Tian
LLP as the Companys independent registered public accounting
firm for the fiscal year ending December31, 2017; and
(v) To vote upon a stockholder proposal relating to proxy access,
if properly presented at the Annual Meeting.

The six nominees were elected, the compensation of named
executive officers was approved (on an advisory basis), the
frequency for future advisory votes on Companys named executive
officers compensation was approved, the appointment of the
independent registered public accounting firm was ratified, and
the stockholder proposal to amend proxy access was not approved
and failed. The results of the voting were as follows:

Election of Directors

VotesFor VotesWithheld BrokerNon-votes

Jon S. Saxe

33,897,004 813,013 5,554,296

Friedhelm Blobel, Ph.D.

34,299,422 410,595 5,554,296

Nancy T. Chang, Ph.D.

33,903,476 806,541 5,554,296

Richard J. Hawkins

31,268,488 3,441,529 5,554,296

Gregg A. Lapointe

34,178,410 531,607 5,554,296

Simon Li

33,903,289 806,728 5,554,296
VotesFor VotesAgainst Abstentions BrokerNon-votes

Approval of Executive Compensation

33,121,822 1,326,662 261,533 5,554,296
1Year 2Years 3Years Abstentions BrokerNon-votes

Approval of Frequency of Advisory Vote

24,412,463 41,073 10,000,523 255,958 5,554,296
VotesFor VotesAgainst Abstentions

Approval of independent registered public accounting firm

39,928,835 61,668 273,810
VotesFor VotesAgainst Abstentions BrokerNon-votes

Approval of shareholder proposal to amend proxy access

9,624,383 24,413,019 672,615 5,554,296


About SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company’s development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

An ad to help with our costs